Email Alert RSS
Volume 14 Issue 6
Nov.  2023
Turn off MathJax
Article Contents
Abstract
References
Related Articles
WEN Qiang, WANG Renfei, HUANG Rui, ZHANG Yuelun, LIN Yansong, Chinese Society of Clinical Oncology Nuclear Medicine Expert Committee. Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer(2023 edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1197-1202. DOI: 10.12290/xhyxzz.2023-0342
Citation: WEN Qiang, WANG Renfei, HUANG Rui, ZHANG Yuelun, LIN Yansong, Chinese Society of Clinical Oncology Nuclear Medicine Expert Committee. Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer(2023 edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1197-1202. DOI: 10.12290/xhyxzz.2023-0342
shu

Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer(2023 edition)

  • 1.

    Department of Nuclear Medicine, China-Japan Union Hospital, Jilin University, Changchun 130033, China

  • 2.

    Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China

  • 3.

    Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China

  • 4.

    Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 5.

    Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-072

More Information
  • Corresponding author:

    LIN Yansong, E-mail: Linys@pumch.cn

  • Received Date: July 22, 2023
  • Accepted Date: August 01, 2023
  • Available Online: August 21, 2023
  • Issue Publish Date: November 29, 2023
    Graphical Abstract
    • Abstract
  • To further standardize the clinical diagnosis and treatment decisions of radioiodine refractory differentiated thyroid cancer (RAIR-DTC) in China, it is urgent to establish clinical diagnosis and treatment management guidelines based on evidence-based medical data to scientifically guide the diagnosis and treatment of RAIR-DTC. By referring to the World Health Organization Guidelines Development Manual andfollowing the protocol of devising evidence-based guidelines, we have registered and written the prospectus of Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer. We will also develop and release official guidance documents. This guidelines prospectus mainly introduces the significance, purpose, target population, user population, guidelines formulation team members, collection and determination of clinical issues and outcome indicators, acquisition, evaluation, and synthesis of evidence, as well as generation of recommendations and other guidelines formulation methods and processes of the Guidelines for the Diagnosis, Treatment, and Management of Iodine Refractory Differentiated Thyroid Cancer.
    • FullText(HTML)
    • References (24)
  • [1]
    Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016[J]. J Nat Cancer Center, 2022, 2: 1-9. DOI: 10.1016/j.jncc.2022.02.002
    [2]
    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26: 1-133. DOI: 10.1089/thy.2015.0020
    [3]
    刘延晴, 林岩松. 碘难治性分化型甲状腺癌诊治策略及预后[J]. 中国实用外科杂志, 2019, 39: 216-220. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK201903007.htm
    [4]
    王任飞, 王勇, 石峰, 等. 碘难治性分化型甲状腺癌的诊治管理共识(2019年版)[J]. 中国癌症杂志, 2019, 29: 476-480. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ201906015.htm
    [5]
    Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol Metab, 2006, 91: 2892-2829. DOI: 10.1210/jc.2005-2838
    [6]
    Robin G, Michelle M, Dianne MW, et al. Clinical Practice Guidelines We Can Trust[M]. Washington (DC): National Academies Press (US), 2011.
    [7]
    Brożek JL, Akl EA, Alonso CP, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines[J]. Allergy, 2009, 64: 669-677. DOI: 10.1111/j.1398-9995.2009.01973.x
    [8]
    Howard B, Mark H, Holger JS, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64: 401-406. DOI: 10.1016/j.jclinepi.2010.07.015
    [9]
    拜争刚, 刘少堃, 黄崇斐, 等. 定性系统评价证据分级工具: CERQual简介[J]. 中国循证医学杂志, 2015, 15: 1465-1470. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201512015.htm
    [10]
    Melissa CB, Michelle EK, George PB, et al. AGREE Ⅱ: advancing guideline development, reporting and evaluation in health care[J]. CMAJ, 2010, 182: E839-E842. DOI: 10.1503/cmaj.090449
    [11]
    张方圆, 沈傲梅, 马婷, 等. 中国癌症症状管理实践指南计划书[J]. 护理研究, 2018, 32: 8-12. https://www.cnki.com.cn/Article/CJFDTOTAL-SXHZ201801005.htm
    [12]
    Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336: 924-926. DOI: 10.1136/bmj.39489.470347.AD
    [13]
    Guyatt GH, Oxman AD, Kunz R, et al. GRADE指南: Ⅱ. 构建问题、确定重要结果[J]. 中国循证医学杂志, 2011, 11: 446-450. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ202112011.htm
    [14]
    Beverley JS, Barnaby CR, George W, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interven-tions, or both[J]. BMJ, 2017, 358: j4008.
    [15]
    熊俊, 陈日新. 系统评价/Meta分析方法学质量的评价工具AMSTAR[J]. 中国循证医学杂志, 2011, 11: 1084-1089. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201109016.htm
    [16]
    Chen Y, Yang K, Marušic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166: 128-132.
    [17]
    Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384: 319-328. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60421-9/fulltext
    [18]
    Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372: 621-630. https://pubmed.ncbi.nlm.nih.gov/25671254/
    [19]
    Chi Y, Gao M, Zhang Y, et al. Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase Ⅱ trial[J]. Ann Oncol, 2020, 31: S1347.
    [20]
    Lin YS, Qin SK, Yang H, et al. Multicenter Randomized Double-Blind Phase Ⅲ Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer[J]. Clin Cancer Res, 2023, 29: 2791-2799.
    [21]
    Lin Y, Qin S, Li Z, et al. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial[J]. JAMA Oncol, 2021, 8: 242-250. https://pubmed.ncbi.nlm.nih.gov/34913959/
    [22]
    Chen J, Ji Q, Bai C, et al. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase Ⅱ Trial[J]. Thyroid, 2020, 30: 1245-1253.
    [23]
    Brose MS, Robinson BG, Sherman SI, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial[J]. Cancer, 2022, 128: 4203-4212.
    [24]
    Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines[J]. BMJ, 2016, 353: i2089. https://pubmed.ncbi.nlm.nih.gov/27353417/
    • Related Articles

  • Related Articles

    [1]WANG Zhaojian, MA Xuda, XIE Jiangmiao, ZOU Kun, LONG Xiao. Protocol for the Development of Chinese Guideline for the Diagnosis and Management of Localized Scleroderma[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(6): 1311-1317. DOI: 10.12290/xhyxzz.2024-0656
    [2]ZHANG Shan, LIU Jie. Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1.2024) Based on the Current Diagnosis and Treatment Status of China[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1029-1037. DOI: 10.12290/xhyxzz.2024-0605
    [3]TIAN Zhuang, ZHANG Shuyang. Interpretation on Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 801-806. DOI: 10.12290/xhyxzz.2024-0292
    [4]JIN Shangyi, TIAN Xinping. Interpretation on the Chinese Guideline for the Diagnosis and Treatment of Takayasu's Arteritis (2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 560-566. DOI: 10.12290/xhyxzz.2024-0209
    [5]LIANG Yan. Interpretation on the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guidelines for the Management of Patients with Chronic Coronary Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 312-319. DOI: 10.12290/xhyxzz.2024-0043
    [6]WANG Wei, ZHANG Yuelun, GAO Sihao, SONG Hongmei. Protocol for the Development of the Guidelines for the Genetic Diagnosis of Autoinflammatory Diseases in China[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 241-246. DOI: 10.12290/xhyxzz.2023-0077
    [7]LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271
    [8]WANG Lin, SONG Hongmei. Interpretation on Chinese Guidelines for the Diagnosis and Treatment of Childhood-onset Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 412-420. DOI: 10.12290/xhyxzz.2022-0018
    [9]Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society, Gitelman Syndrome Consensus Working Group. Expert Consensus for the Diagnosis and Treatment of Gitelman Syndrome in China (2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 902-912. DOI: 10.12290/xhyxzz.2021-0555
    [10]Hua ZHAO, Xiao-ting WANG, Da-wei LIU, Chinese Critical Ultrasound Study Group. Evaluating Value of Modified Critical Care Ultrasonic Examination Protocol for the Patients Unplanned Admission to the ICU[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(5): 437-444. DOI: 10.3969/j.issn.1674-9081.2018.05.012

  • Cited by

    Periodical cited type(5)

    1. 向辉，贾晓斌，柯贤锋，王曦煜，李强. 甲状腺乳头状癌组织中miR-497-5p、FOXP4表达与病理参数和预后的关系. 疑难病杂志. 2025(02): 209-213+219 .
    2. 施嫣嫣，黄玉宇. 372例患者新型抗肿瘤药物使用合理性分析. 中国医院用药评价与分析. 2025(02): 220-222+226 .
    3. 邵建兰，彭俊文，周琼莱. 甲状腺手术患者术前血常规及凝血指标对术后出血的预测价值分析. 浙江创伤外科. 2024(02): 291-293 .
    4. 程若川，刘文. 远处转移甲状腺癌的诊治异同点及评价. 中国实用外科杂志. 2024(06): 630-636 .
    5. 王招荐，马旭达，谢江淼，邹锟，龙笑. 《中国局限性硬皮病诊断与治疗指南》计划书. 协和医学杂志. 2024(06): 1311-1317 . 本站查看

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (568) PDF downloads (211) Cited by(5)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close